IRIX Stock Up 4% As Q1 Loss Narrows Y/Y on Glaucoma Product Growth

IRIDEX posts a narrower year-over-year net loss per share in Q1'26 as strong glaucoma product sales and lower operating costs helped offset weakness in retina sales and supply-chain disruptions.

Zacks Investment Research • May 25, 2026

IRIDEX Corporation (IRIX) Q1 2026 Earnings Call Transcript

IRIDEX Corporation (IRIX) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 19, 2026

Iridex Reports First Quarter 2026 Financial Results

MOUNTAIN VIEW, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the first quarter ended April 4, 2026.

GlobeNewsWire • May 19, 2026

Iridex to Report First Quarter 2026 Financial Results on May 19, 2026

MOUNTAIN VIEW, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced plans to release financial results for the first quarter 2026 and provide a business update after the close of trading on May 19, 2026.

GlobeNewsWire • May 5, 2026

Iridex Announces New Partnership with EyeProGPO to Expand Member Access to Retina Laser Technology

MOUNTAIN VIEW, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced a new partnership with EyeProGPO, an ophthalmology-focused group purchasing organization serving ophthalmology practices, ambulatory surgery centers (ASC), and hospitals across the United States.

GlobeNewsWire • Apr 7, 2026

Iridex's Q4 Loss Narrows Year Over Year on Retina Sales Growth

IRIX incurs narrower year-over-year loss per share in Q4 as growth in retina systems and glaucoma probes boosts revenues, though margins remain pressured by higher costs.

Zacks Investment Research • Apr 1, 2026

IRIDEX Corporation (IRIX) Q4 2025 Earnings Call Transcript

IRIDEX Corporation (IRIX) Q4 2025 Earnings Call Transcript

Seeking Alpha • Mar 26, 2026

Iridex Reports Fourth Quarter and Full Year 2025 Financial Results

Strong Q4 and Full Year 2025 Revenue Performance Underpinned by Continued Operational Efficiencies Strong Q4 and Full Year 2025 Revenue Performance Underpinned by Continued Operational Efficiencies

GlobeNewsWire • Mar 26, 2026

Iridex to Report Fourth Quarter and Full Year 2025 Financial Results on March 26, 2026

MOUNTAIN VIEW, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced plans to release financial results for the fourth quarter and full year 2025 and provide a business update after the close of trading on March 26, 2026.

GlobeNewsWire • Mar 12, 2026

Iridex Announces Plans to Relocate Headquarters

MOUNTAIN VIEW, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced its intent to relocate the Company's headquarters from Mountain View, California to San Jose, California.

GlobeNewsWire • Feb 2, 2026